Strides Pharma Science (NSE:STAR) Treasury Stock: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
68 GF Score
Price ₹1,071.10
GF Value ₹780.73
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Treasury Stock?

Strides Pharma Science NSE:STAR -0.27% 68 Treasury Stock is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹780.73 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Strides Pharma Science's treasury stock for the quarter that ended in Mar. 2026 was ₹0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Strides Pharma Science Treasury Stock Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Treasury Stock Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:STAR
68GF Score
Strides Pharma Science Ltd NSE:STAR
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of ₹0 Mil mean?
Strides Pharma Science (NSE:STAR) has a Treasury Stock of ₹0 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Strides Pharma Science and its competitors.
Is Strides Pharma Science's Treasury Stock too high?
Strides Pharma Science's current Treasury Stock is ₹0 Mil. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Treasury Stock compare to ZTS and UTHR?
Strides Pharma Science's Treasury Stock of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Drug Manufacturers company?
A good Treasury Stock depends on the Drug Manufacturers industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Strides Pharma Science and its competitors. Strides Pharma Science's current Treasury Stock is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹780.73, compared to a current price of ₹1,071.10 — trading 37.2% above its estimated fair value. The current Treasury Stock is ₹0 Mil. Strides Pharma Science's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Treasury Stock is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,071.10 is trading 37.2% above its estimated GF Value™ of ₹780.73. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Treasury Stock: ₹0 Mil
  • GF Value™: ₹780.73 vs. price of ₹1,071.10 (37.2% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score

Get the complete analysis for NSE:STAR

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,071.10
Price
₹780.73
GF Value